As more than 60% of new drugs fail in phase 2, we have chosen to focus our activities since 2000 on preclinical in Vivo Efficacy Studies to offer better predictability and anticipate clinical results. Syncrosome is a preclinical CRO wich offers relevant disease models, cutting-edge techniques, specific Biomarkers and a comprehensive background of physiopathology to assist drug discovery companies in selecting their compounds. We have developped and validated so far more than 15 preclinical disease models, and our flexible and human-sized organization can design and operate tailored in vivo experimental protocols to give you appropriate answers. Our main activities consit in :
- In vivo Drug Efficacy Studies (preclinical pharmacology) for:
o Central Nervous Sytem (Parkinson, stroke, neuroinflamation etc….),
o Cardiovascular and Metabolic disease (Ischemia Reperfusion, Heart Failure…)
o Respiratory (asthma, COPD, cough)
o Gastro-intestinal (IBD, IBS, gut motility, gastric emptying, emesis….) Diseases.
- CNS-PK with a special focus in the study of the Blood Brain Barrier passage and/or Neurotransmitter monitoring (Dopamine….)
- Early bioavailibity studies (PK/PD) on rodents and non-rodents. Beyond sound science, our proactive approach combining pharmacological expertise, appropriate study design, relevant, endpoints, performed on relevant and complementary disease models, provide our clients with the most relevant data. Besides our premium services and track record of success, we pay especial attention to ethics, animal welfare, sustainable development and to the validation of up to date techniques.
